BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuno N, Kurimoto K, Fukushima M, Hayakawa T, Shibata T, Suzuki T, Sakakibara A, Katada N, Nakano S, Takayama T. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions. Pancreas 1994;9:725-30. [PMID: 7531333 DOI: 10.1097/00006676-199411000-00009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Hayakawa T, Naruse S, Kitagawa M, Ishiguro H, Kondo T, Kurimoto K, Fukushima M, Takayama T, Horiguchi Y, Kuno N. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol. 1999;25:23-29. [PMID: 10211418 DOI: 10.1385/IJGC: 25: 1: 23] [Reference Citation Analysis]
2 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
3 Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. [PMID: 17097848 DOI: 10.1016/j.ejso.2006.10.004] [Cited by in Crossref: 467] [Cited by in F6Publishing: 413] [Article Influence: 31.1] [Reference Citation Analysis]
4 Tang Y, Cui Y, Zhang S, Zhang L. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog Mol Biol Transl Sci 2019;162:121-40. [PMID: 30905445 DOI: 10.1016/bs.pmbts.2019.01.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Frena A. SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker. Int J Biol Markers 2001;16:189-97. [DOI: 10.1177/172460080101600306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997;11:225-31. [PMID: 9219065 DOI: 10.1002/(sici)1098-2825(1997)11:4<225::aid-jcla9>3.0.co;2-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Farina A, Delhaye M, Lescuyer P, Dumonceau JM. Bile proteome in health and disease. Compr Physiol 2014;4:91-108. [PMID: 24692135 DOI: 10.1002/cphy.c130016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
8 Haycox, Lombard, Neoptolemos, Walley. Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer: REVIEW: DETECTION AND DIAGNOSIS OF PANCREATIC CANCER. Alimentary Pharmacology & Therapeutics 1998;12:937-48. [DOI: 10.1046/j.1365-2036.1998.00393.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
9 Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:227-251. [PMID: 16549326 DOI: 10.1016/j.bpg.2005.10.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
10 Wong T, Howes N, Threadgold J, Smart HL, Lombard MG, Gilmore I, Sutton R, Greenhalf W, Ellis I, Neoptolemos JP. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology. 2001;1:486-509. [PMID: 12120229 DOI: 10.1159/000055852] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
11 Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas. 2007;34:318-324. [PMID: 17414054 DOI: 10.1097/mpa.0b013e31802ee9c7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
12 Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E, Geraghty JG. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 1996;5:49-63. [PMID: 8853239 DOI: 10.1016/s0960-7404(96)80001-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Rychlíková J, Vecka M, Jáchymová M, Macášek J, Hrabák P, Zeman M, Vávrová L, Řoupal J, Krechler T, Ák A. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomark 2016;17:55-65. [PMID: 27314293 DOI: 10.3233/CBM-160617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Thyregod Jørgensen M, Bau Mortensen M, Gerdes A, Schaffalitzky De Muckadell OB. Familial pancreatic cancer. Scandinavian Journal of Gastroenterology 2009;43:387-97. [DOI: 10.1080/00365520701775229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]